Remedial and cleaning efforts were associated with a decrease in the diversity of dustborne fungi in one of the buildings. This, as well as the disappearance of certain material-associated species, supports the assumption that remediation was effective in the removal of the fungal burden contributed by MG-132 purchase indoor mold growth sources. In the second location, clear indications of an intervention effect on the

diversity were not seen. Due to a delay in remediation p53 activator schedules the interval between completion of the remediation and post-remediation sampling was short, which may explain the increase in the abundance of material-associated fungi in post-remediation dust; despite efforts to prevent the spread of contamination, fungal particles aerosolized during remediation may have spread, not being sufficiently removed by post-remedial cleaning. In addition, there was an unexpected diversification in the reference

building’s GSK690693 solubility dmso microbial profile, which undermined the case-control comparison. The diversification may have been caused by an increase in the transfer of fungal material from outdoors. This hypothesis is supported by the appearance of many probably outdoor-related phylotypes in the clone libraries. Yet the diversification included many species that may proliferate indoors, and thus the occurrence of water damage in the reference building cannot be ruled out. In Location-2, the considerable distance between the index and reference buildings also challenged the comparison. These

findings highlight the strong variation in indoor mycobiota within and between buildings, the uniqueness of individual buildings’ microbial profiles and the complexity of potential sources. For these reasons, the choice and matching of reference building for each study building is crucial. In general, our findings are only suggestive due to the deep normal variation between buildings and the small building number, and should be further examined with larger data sets. D-malate dehydrogenase Comparison of methods Of all methods tested, clone library analysis provided the most thorough inventory of fungal diversity in settled dust. Nevertheless, a comparison of the sequencing results with qPCR results (a technique with higher analytical sensitivity) showed that many species present in the samples were not represented by the libraries. The species only detected by qPCR tended to be those of lower qPCR cell counts, whereas highly abundant species were much better represented in the clone libraries. Taking into account the semiquantitative nature of clone library results and the presently deficient species-level information of potential building-associated fungi, the usefulness of clone library sequencing for assessment of building sources remains uncertain. This uncertainty also arises from the universal nature of the technique, i.e. its sensitivity in detecting background diversity acting as a dampening factor on the ability to detect shifts in indicator species.

Eur J Appl Physiol 2001, 86:142–149.PubMed 192. Camilleri M, Madsen K, Spiller R, Van Meerveld BG, Verne GN: Intestinal

barrier function in health and gastrointestinal disease. Neurogastroenterol Motil 2012, 24:503–512.PubMed 193. Ivy JL, Kammer L, Ding Z, Wang B, Bernard JR, Liao YH, Hwang PI3K Inhibitor Library cell line J: Improved cycling time-trial performance after ingestion of a caffeine energy drink. Int J Sport Nutr Exerc Metab 2009, 19:61–78.PubMed 194. McNaughton LR, Lovell RJ, Siegler J, Midgley AW, Moore L, Bentley DJ: The effects of caffeine ingestion on time trial cycling performance. Int J Sports Physiol Perform 2008, 3:157–163.PubMed 195. Carr A, Dawson B, Schneiker K, Goodman C, Lay B: Effect of caffeine supplementation on repeated sprint running performance. Daporinad datasheet J Sports Med Phys Fitness 2008, 48:472–478.PubMed 196. Glaister M, Howatson G, Abraham CS, Lockey RA, Goodwin JE, Foley P, McInnes G: Caffeine supplementation and this website multiple sprint running performance. Med Sci Sports Exerc 2008, 40:1835–1840.PubMed 197. Green JM, Wickwire PJ, McLester JR, Gendle

S, Hudson G, Pritchett RC, Laurent CM: Effects of caffeine on repetitions to failure and ratings of perceived exertion during resistance training. Int J Sports Physiol Perform 2007, 2:250–259.PubMed 198. Woolf K, Bidwell WK, Carlson AG: The effect of caffeine as an ergogenic aid in anaerobic exercise. Int J Sport Nutr Exerc Metab 2008, 18:412–429.PubMed 199. Duncan MJ, Oxford SW: The effect of caffeine ingestion on mood state and bench press performance to failure. J Strength Cond Res 2011, 25:178–185.PubMed

200. Williams AD, Cribb PJ, Cooke MB, Hayes A: The effect of ephedra and caffeine on maximal strength and power in resistance-trained athletes. J Strength Cond Res 2008, 22:464–470.PubMed 201. Hendrix CR, Housh TJ, Mielke M, Zuniga JM, Camic CL, Johnson GO, Schmidt RJ, Housh DJ: Acute effects of a caffeine-containing supplement on bench press and leg SPTLC1 extension strength and time to exhaustion during cycle ergometry. J Strength Cond Res 2010, 24:859–865.PubMed 202. Nawrot P, Jordan S, Eastwood J, Rotstein J, Hugenholtz A, Feeley M: Effects of caffeine on human health. Food Addit Contam 2003, 20:1–30.PubMed 203. Tarnopolsky MA, Atkinson SA, MacDougall JD, Sale DG, Sutton JR: Physiological responses to caffeine during endurance running in habitual caffeine users. Med Sci Sports Exerc 1989, 21:418–424.PubMed 204. Bazzarre TL, Kleiner SM, Litchford MD: Nutrient intake, body fat, and lipid profiles of competitive male and female bodybuilders. J Am Coll Nutr 1990, 9:136–142.PubMed 205. Kleiner SM, Bazzarre TL, Ainsworth BE: Nutritional status of nationally ranked elite bodybuilders. Int J Sport Nutr 1994, 4:54–69.PubMed 206. Hickson JF Jr, Johnson TE, Lee W, Sidor RJ: Nutrition and the precontest preparations of a male bodybuilder. J Am Diet Assoc 1990, 90:264–267.PubMed 207.

Owing to the deoxidized

plentiful crystal nuclei, the higher ion concentration facilitated the form of a two-dimensional thin film at a lower potential in the electrolyte. When the ion concentration was lower, the amount of deoxidized crystal nuclei did not afford the needs of thin film growth, and the two-dimensional growth form would be replaced by the selleck chemicals llc one-dimensional growth form. The schematic diagrams of the experimental setup were shown in Figure  1b. Figure 1 Scanning electron microscopy image of the PbTe/Pb nanostructure. (a) The representative SEM image of PbTe/Pb nanostructure arrays with a field of view of 30 μm (w) × 20 μm (h). (b) The SEM image of the single PbTe/Pb nanostructure. The upper right insert figure gives the central configuration schematic of the electrochemical HER2 inhibitor cell. The lower left insert figure gives the applied voltage waveform. The applied voltage varies from 0.5 to 0.9 V in a square waveform with see more 1 Hz frequency. The electrodeposition of the PbTe/Pb nanostructure arrays was carried out by applying a square wave potential with a

frequency of 1 Hz (in Figure  1b) across the ultrathin layer. The electrolyte was prepared using analytical reagent Pb(NO3)2, TeO2 (Fluka, Sigma-Aldrich Corporation, St. Louis, MO, USA), and Millipore water (Millipore Co., Billerica, MA, USA). The ion concentrations of Pb2+ and HTeO2

+ in the electrolyte were 0.005 and 0.001 M, respectively. The pH value of the electrolyte was adjusted to 1.87 by nitric acid. The treated silicon substrate (20 × 20 mm2) (Fluka) was first placed on the Peltier element. Silicon was treated using chemical erosion and oxidation process, which would bring an insulation and uniform thickness of the SiO2 layer on the surface of the silicon wafer. Next, the two parallel lead foil electrodes with 30-μm thickness (Fluka) were placed on the substrate and filled with the electrolyte. A cover glass was put on the electrodes, and the simple electrolytic cell was assembled. After that, the temperature Sirolimus in vitro control system consisted of a circulating water bath, and the Peltier element was used to solidify the electrolyte. Due to the partitioning effect, the solute in the electrolyte could be partially expelled from the solid in the solidification process. The concentrated electrolyte layer with 300-nm thickness was formed between the ice from the electrolyte and the SiO2/Si substrate when the temperature dropped to −5.20°C. The temperature played an important role to the control of the electrolyte layer thickness and concentration. The lower temperature could cause the solute in the electrolyte layer to be further expelled from the solid, which made the concentration of the electrolyte layer more concentrated.

J Clin Microbiol 2001,39(12):4549–4553.PubMedCrossRef 17. Johnson TJ, Wannemuehler Y, Doetkott C, Johnson SJ, Rosenberger SC, Nolan LK: Identification of minimal predictors of avian pathogenic Escherichia coli virulence for use as a rapid diagnostic tool. J Clin Microbiol 2008,46(12):3987–3996.PubMedCrossRef 18. Ron EZ: Host specificity of septicemic Escherichia coli : human and avian pathogens. Curr Opin Microbiol 2006,9(1):28–32.PubMedCrossRef 19. Johnson JR, Oswald E, O’Bryan TT, Kuskowski

Napabucasin MA, Spanjaard L: Phylogenetic distribution of virulence-associated genes among Escherichia coli isolates associated with neonatal bacterial meningitis in the Netherlands. J Infect Dis 2002,185(6):774–784.PubMedCrossRef 20. Miller VL, Mekalanos JJ: A novel suicide vector and its use in construction of insertion mutations: osmoregulation of outer membrane proteins

and virulence determinants in Vibrio cholerae requires toxR . J Bacteriol 1988,170(6):2575–2583.PubMed 21. Guzman LM, Belin D, Carson TSA HDAC manufacturer MJ, Beckwith J: Tight regulation, modulation, and high-level expression by vectors containing the arabinose PBAD promoter. J Bacteriol 1995,177(14):4121–4130.PubMed 22. Datsenko KA, Wanner BL: One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci USA 2000,97(12):6640–6645.PubMedCrossRef 23. Schouler C, Koffmann F, Amory C, Leroy-Setrin S, Moulin-Schouleur M: Genomic subtraction for the identification of putative new virulence factors of an avian pathogenic

Escherichia coli strain of O2 serogroup. Microbiology 2004,150(Pt 9):2973–2984.PubMedCrossRef 24. Moulin-Schouleur M, Reperant M, Laurent S, Bree A, Mignon-Grasteau S, Germon P, Rasschaert D, Schouler C: Extraintestinal pathogenic Escherichia coli strains of avian and human origin: link between phylogenetic relationships and common virulence patterns. J Clin Microbiol 2007,45(10):3366–3376.PubMedCrossRef 25. Brzuszkiewicz E, Bruggemann H, Liesegang H, Emmerth M, Olschlager T, Nagy G, Albermann K, Wagner C, Buchrieser SPTLC1 C, Emody L, et al.: How to become a uropathogen: comparative genomic analysis of extraintestinal pathogenic Escherichia coli strains. Proc Natl Acad Sci USA 2006,103(34):12879–12884.PubMedCrossRef 26. Welch RA, Burland V, Plunkett G, Redford P, Roesch P, Rasko D, Buckles EL, Liou SR, Boutin A, PF-3084014 mw Hackett J, et al.: Extensive mosaic structure revealed by the complete genome sequence of uropathogenic Escherichia coli . Proc Natl Acad Sci USA 2002,99(26):17020–17024.PubMedCrossRef 27. Ewers C, Antao EM, Diehl I, Philipp HC, Wieler LH: Intestine and environment of the chicken as reservoirs for extraintestinal pathogenic Escherichia coli strains with zoonotic potential. Appl Environ Microbiol 2009,75(1):184–192.PubMedCrossRef 28.

Western blot analyses revealed that Doxo and Gem treatment alone increased p53 this website levels (Figure 3A). When NQO1-knockdown-KKU-100 cells were treated with chemotherapeutic agents, p53 level was enhanced further by all 3 agents (Figure 3A). Then, we examined the expression levels of some p53 downstream proteins, i.e. p21, cyclin D1, and Bax protein. Similar to p53, p21 and Bax were over-expressed by the drug treatments (Figure 3B, 3D). In contrast, in the NQO1 knockdown cells, treatment with chemotherapeutic agents strongly suppressed the cyclin D1 level (Figure 3C). In the non-target siRNA transfected KKU-100 cells, Doxo and Gem, but not 5-FU, treatments increased cyclin D1 expression

(Figure 3C). Figure 3 Altered expressions of proteins related to cell proliferation and apoptosis pathways. A-D, Expressions of proteins related to cell proliferation and apoptosis pathways. KKU-100 with NQO1 knocked down cells were exposed Trichostatin A chemical structure click here to chemotherapeutic agents; 5-FU (3 μM), Doxo (0.1 μM), and Gem (0.1 μM) for 24 hr. Whole cell lysates were prepared after indicated treatment and Western blot analysis was conducted using anti-p53 (A), -p21 (B), -cyclin D1 (C), -Bax (D) and -β-actin antibodies. The relative bars that were normalized with β-actin as a loading control of each band is shown below the Western blot images. Data represent mean ± SEM, each from three separated experiments. *p < 0.05

vs the treated non-targeting knocked down cells. **p < 0.05 vs the untreated non-targeting knocked down cells. Over-expression of NQO1 in CCA cells induces drug resistance against chemotherapeutic agents Since KKU-M214 cells naturally express relatively low level of NQO1, effects of NQO1 over-expression by transient transfection with NQO1 expression vector on the susceptibility of cells to chemotherapeutic agents was evaluated. After transfection, the NQO1 enzyme activity in the transfected

cells was elevated approximately 2.5-fold and the NQO1 protein level was 2.25-fold higher than the control vector (Figure 4A-B), indicating Phospholipase D1 that NQO1 construct was efficiently expressed in KKU-M214 cells. Then, NQO1-over-expressed KKU-M214 cells were exposed to 5-FU and Gem for 48 hr, and to Doxo for 24 hr. The results showed that the cytotoxicity of 5-FU, Doxo, and Gem were markedly decreased for NQO1-over-expressed KKU-M214 cells (Figure 4C-E), indicating the protective effect of NQO1. Figure 4 Effects of NQO1 over-expression on the susceptibility of KKU-M214 cells to chemotherapeutic agents (5-FU, Doxo, and Gem). A-B, Effect of NQO1 over-expression on mRNA and protein levels of NQO1 in KKU-M214 cells. The pCMV6-XL5-NQO1 (wild type NQO1) or pCMV6-XL5 (control vector) was transfected to KKU-M214 for 24 hr. The whole cells were collected for NQO1 enzyme activity assay (A) and Western blot analysis (B). The data represent mean ± SEM, each from three experiments. *p < 0.05 vs the control vector transfected cells.

Antoce et al. [11] successfully used calorimetric methods for the determination of https://www.selleckchem.com/products/idasanutlin-rg-7388.html inhibitory effects of alcohols on yeasts to avoid computational

errors based on direct assessment of bioactivity using turbidity. An important feature of this method was first noted in the study of Garedew et al. [12]: microcalorimetry can provide rapid detection of bacterial growth. If the number of bacteria in a calorimeter ampoule rise to about 104 cfu Adavosertib they can be detected by their heat production. If growth continues, the heat flow rate will continue to rise for some time. This was used to advantage in our laboratory in a recently published study in which we employed isothermal microcalorimetry for rapid detection of MSSA and other microorganisms

in blood products, i.e. platelet concentrates [13]. Still more recently, we also successfully determined the MIC of cefoxitin for mTOR inhibitor a MRSA strain and a MSSA strain [14]. However, IMC did not decrease the time for MIC determination because MICs are based on detection of growth at 24 hours. But more importantly, IMC with media containing added antibiotic concentrations provided a means for rapidly differentiating between MRSA and MSSA. In addition, it was apparent that the nature of the heatflow curves at subinhibitory concentrations of the antibiotic might provide new insights into ID-8 the way in which antibiotics affect growth rates. Therefore, we conceived this study. To further evaluate IMC we have now determined the MICs of 12 antibiotics for reference strains of five organisms, E. coli ATCC25922, S. aureus ATCC29213, Pseudomonas aeruginosa ATCC27853, Enterococcus faecalis ATCC29212, and Streptococcus agalactiae ATCC27956. In the interest of brevity we report here only the results for E. coli ATCC25922 and S. aureus ATCC29213 as representatives for Gram- and Gram+ bacteria, respectively. Results As is evident in Figs. 1, 2, 3, 4, 5 and 6, the heat flow rate signals from blank ampoules (no inoculum) never

departed appreciably from baseline over the time of measurement. That is, the blanks produced no appreciable heat flow – especially compared to the peak values (often > 100 μW) measured when bacteria were present. Thus all heat flow signals above baseline could be attributed to bacterial activity and growth. Table 1 provides an overview comparing the MICs determined by IMC with those determined by a standard turbidometric method. It also provides a comparison of key growth-related calorimetric parameters determined at subinhibitory concentrations just below the MIC value: t delay (delay in time of onset of detectable heat flow), and P max (maximum rate of heat production). These and other calorimetric parameters pertinent to this study and derived from the data are explained and used in the Discussion section.

Eastell R, Hannon RA (2008) Biomarkers Blebbistatin cell line of bone health and osteoporosis risk. Proc Nutr Soc 67(2):157–162PubMedCrossRef 17. El Maghraoui A, Tellal S, Chaouir S et al (2005) Bone turnover markers, anterior pituitary and gonadal ABT-888 mouse hormones, and bone mass evaluation using quantitative computed tomography in ankylosing spondylitis. Clin Rheumatol 24(4):346–351PubMedCrossRef 18. Karberg K, Zochling J, Sieper J et al (2005) Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. J Rheumatol 32(7):1290–1298PubMed 19. Sarikaya S, Basaran A, Tekin Y et al (2007) Is osteoporosis generalized or localized to central skeleton in ankylosing spondylitis? J Clin

Rheumatol 13(1):20–24PubMedCrossRef 20. Yilmaz N, Ozaslan J (2000) Biochemical bone turnover markers in patients with ankylosing spondylitis. Clin Rheumatol 19(2):92–98PubMedCrossRef 21. Vosse D, Landewe R, Garnero P et al (2008) Association of markers of bone- and cartilage-degradation with radiological changes at baseline and after 2 years follow-up in patients with ankylosing spondylitis. Rheumatology 47(8):1219–1222PubMedCrossRef 22. Kanis JA, McCloskey EV, Johansson H et al (2008) A reference standard for the description of osteoporosis. Bone 42(3):467–475PubMedCrossRef 23. Baek HJ, Kang SW, Lee YJ et al (2005) Osteopenia in men with mild and severe

ankylosing spondylitis. Rheumatol Int 26(1):30–34PubMedCrossRef 24. Lee YS, Schlotzhauer T, Ott SM et al (1997) Skeletal status THZ1 of men with early and late ankylosing spondylitis. Am J Med 103(3):233–241PubMedCrossRef 25. Meirelles ES, Borelli A, Camargo OP (1999) Influence of disease activity and chronicity on ankylosing spondylitis bone mass loss. Clin Rheumatol 18(5):364–368PubMedCrossRef 26. Lange U, Kluge A, Strunk J et al (2005) Ankylosing spondylitis and bone mineral density—what is the ideal tool for Endonuclease measurement? Rheumatol Int 26(2):115–120PubMedCrossRef 27. Bessant R, Keat A (2002) How should clinicians manage osteoporosis in ankylosing spondylitis? J Rheumatol 29(7):1511–1519PubMed 28. van der

Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27(4):361–368PubMedCrossRef 29. Braun J, Davis J, Dougados M et al (2006) First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 65(3):316–320PubMedCrossRef 30. Garrett S, Jenkinson T, Kennedy LG et al (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21(12):2286–2291PubMed 31. Lukas C, Landewe R, Sieper J et al (2009) Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 68(1):18–24PubMedCrossRef 32.

The Forrest classification SB525334 is often used to distinguish endoscopic appearances of bleeding ulcers (Ia spurting active bleeding; Ib oozing active bleeding; IIa visible vessel; IIb adherent clot; IIc flat pigmented spot; III ulcer with a clean base) [116]. In PUB, patients with active bleeding ulcers or a non-bleeding visible vessel in an ulcer bed are at highest risk of re-bleeding and therefore need prompt endoscopic hemostatic therapy. Patients with low-risk stigmata (clean-based ulcer or a pigmented spot

in ulcer bed) do not require endoscopic therapy [81]. Two small randomised trials, and a meta-analysis suggested that a clot should be removed in search of an artery and, when it is selleckchem present, endoscopic treatment should be given, although the management of peptic Thiazovivin ulcers with overlying adherent

clots that are resistant to removal by irrigation is still controversial [98, 117–119]. Endoscopic treatment can be divided into injection (including epinephrine, sclerosants and even normal saline solution), thermal (including monopolar or bipolar cautery and argon plasma coagulation) and mechanical methods (including hemoclips). Often, the choice of which endoscopic therapy employ is based on local preference and expertise. Injection of diluted epinephrine alone is now judged to be inadequate [94]. Cushions of fluid injected into the submucosa compress the artery to stop or slow down bleeding and allow a clear view of the artery. A second modality should be added to induce thrombosis of the artery. Calvet et al. pooled

the results of 16 randomised controlled trials that compared injection of diluted adrenaline alone with injection followed by a second modality, and showed that combination treatment led to substantial reductions in rate of recurrent bleeding (risk reduction from 18,4% to 10,6%), surgery (from 11,3% to 7,6%) and mortality (from 5,1% to 2,6%) [120]. The investigators also compared studies 6-phosphogluconolactonase with or without second look endoscopies after initial endoscopic treatment. Rebleeding was higher in the group given adrenaline injection alone than in the combination treatment group (15,7% vs. 11,4%). Two other meta-analyses that summarised studies of monotherapies versus dual therapies also concluded that a second modality should be added to injection treatment [108, 121]. The observation suggested that if combination treatment had been instituted at index endoscopy, a second look endoscopy would have been unnecessary, so routine second look endoscopy after initial endoscopic haemostasis is not recommended [122].

Bioinformatics 2004,20(17):3246–3248.PubMedCrossRef 44. Huttley GA, Kelley ST, Knights D, Koenig JE, Ley RE, Lozupone CA, McDonald D, Muegge BD, Pirrung M, Reeder J, Sevinsky JR, Turnbaugh PJ, Walters WA, Widmann J, Yatsunenko T, Zaneveld J, Knight R, Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, Pena AG, Goodrich JK, Gordon JI, et al.: QIIME allows analysis of high-throughput community sequencing data. Nat Meth 2010,7(5):335–336.CrossRef 45. Lee SG, Kim CM, Hwang KS: Development of a software Roscovitine price tool for in silico simulation of Escherichia coli using a visual programming

environment. J Biotechnol 2005,119(1):87–92.PubMedCrossRef 46. Murphy FA, Fauquet CM, Bishop DHL, Ghabrial SA, Jarvis AW, Martelli GP, Mayo MA, GS-9973 nmr Summers MD: Virus Taxonomy: Sizth Report of the International Committee on Taxonomy of Viruses. New York: Springer-Verlag;

1995. Vol. Supplement 10 47. Cole JR, Wang Q, Cardenas E, Fish J, Chai B, Farris RJ, Kulam-Syed-Mohideen AS, McGarrell DM, Marsh T, Garrity GM, Tiedje JM: The Ribosomal Database Project: improved alignments and new tools for rRNA analysis. Nucleic Acids Res 2009, 37:D141-D145.learn more PubMedCentralPubMedCrossRef 48. Whiteley AS, Jenkins S, Waite I, Kresoje N, Payne H, Mullan B, Allcock R, O’Donnell A: Microbial 16S rRNA Ion Tag and community metagenome sequencing using the Ion Torrent (PGM) Platform. J Microbiol Methods 2012,91(1):80–88.PubMedCrossRef 49. Edgar RC: Search and clustering orders

of magnitude faster than BLAST. Bioinformatics 2010,26(19):2460–2461.PubMedCrossRef 50. Caporaso JG, Bittinger K, Bushman FD, DeSantis TZ, Andersen GL, Knight R: PyNAST: a flexible tool for aligning sequences to a template alignment. Bioinformatics 2010,26(2):266–267.PubMedCentralPubMedCrossRef 51. DeSantis TZ, Hugenholtz P, Larsen N, Rojas M, Brodie EL, Keller K, Huber T, Dalevi D, Hu P, Andersen GL: Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Appl Environ Microbiol 2006,72(7):5069–5072.PubMedCentralPubMedCrossRef 52. Li W, Godzik A: Cd-hit: a fast program for clustering cAMP and comparing large sets of protein or nucleotide sequences. Bioinformatics 2006,22(13):1658–1659.PubMedCrossRef 53. Price MN, Dehal PS, Arkin AP: FastTree: computing large minimum evolution trees with profiles instead of a distance matrix. Mol Biol Evol 2009,26(7):1641–1650.PubMedCentralPubMedCrossRef 54. Wang Q, Garrity GM, Tiedje JM, Cole JR: Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol 2007,73(16):5261–5267.PubMedCentralPubMedCrossRef 55. Lozupone C, Hamady M, Knight R: UniFrac–an online tool for comparing microbial community diversity in a phylogenetic context. BMC Bioinforma 2006, 7:371.CrossRef Competing interests The authors declare that they have no competing interests. Authors’ contributions Conceived and designed experiments: DTP.